
Mersana Therapeutics is a biotechnology business based in the US. Mersana Therapeutics shares (MRSN) are listed on the NASDAQ and all prices are listed in US Dollars. Mersana Therapeutics employs 169 staff and has a trailing 12-month revenue of around $11.9 million.
How to buy Mersana Therapeutics stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – MRSN. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
tastyworks
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Mersana Therapeutics stock price (NASDAQ: MRSN)
Use our graph to track the performance of MRSN stocks over time.Mersana Therapeutics shares at a glance
Latest market close | $6.56 |
---|---|
52-week range | $2.68 - $8.34 |
50-day moving average | $6.31 |
200-day moving average | $5.73 |
Wall St. target price | $16.83 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-2.49 |
Buy Mersana Therapeutics stocks from these brokerages
Compare special offers, low fees and a wide range of types of investments among top trading platforms.*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Mersana Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Mersana Therapeutics price performance over time
Historical closes compared with the close of $6.56 from 2023-01-25
1 week (2023-01-20) | 2.50% |
---|---|
1 month (2022-12-27) | 14.89% |
3 months (2022-10-27) | -6.02% |
6 months (2022-07-27) | 15.90% |
1 year (2022-01-27) | 52.56% |
---|---|
2 years (2021-01-27) | -64.48% |
3 years (2020-01-27) | 7.62 |
5 years (2018-01-26) | 16.34 |
Mersana Therapeutics financials
Revenue TTM | $11.9 million |
---|---|
Gross profit TTM | $-131,970,000 |
Return on assets TTM | -48.36% |
Return on equity TTM | -169.48% |
Profit margin | 0% |
Book value | $0.92 |
Market capitalisation | $654.5 million |
TTM: trailing 12 months
Mersana Therapeutics share dividends
We're not expecting Mersana Therapeutics to pay a dividend over the next 12 months.
Mersana Therapeutics share price volatility
Over the last 12 months, Mersana Therapeutics's shares have ranged in value from as little as $2.68 up to $8.338. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Mersana Therapeutics's is 1.7175. This would suggest that Mersana Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Mersana Therapeutics overview
Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc.
Mersana Therapeutics in the news
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
With Upcoming Ovarian Cancer Data, Analyst Sees 100% Upside For Mersana Therapeutics
Frequently asked questions
What percentage of Mersana Therapeutics is owned by insiders or institutions?Currently 1.141% of Mersana Therapeutics shares are held by insiders and 97.033% by institutions. How many people work for Mersana Therapeutics?
Latest data suggests 169 work at Mersana Therapeutics. When does the fiscal year end for Mersana Therapeutics?
Mersana Therapeutics's fiscal year ends in December. Where is Mersana Therapeutics based?
Mersana Therapeutics's address is: 840 Memorial Drive, Cambridge, MA, United States, 02139 What is Mersana Therapeutics's ISIN number?
Mersana Therapeutics's international securities identification number is: US59045L1061 What is Mersana Therapeutics's CUSIP number?
Mersana Therapeutics's Committee on Uniform Securities Identification Procedures number is: 59045L106
More guides on Finder
-
How to buy TXO Energy (TXO) stock when it goes public
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock when it goes public
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
-
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
-
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
-
How to research stocks
Learn about stock analysis and how to use it to find the right company to buy.
Ask an Expert